Zai Lab Limited (ZLAB) Stock Jumps 6.8%: Will It Continue to Soar?

By Zacks Equity Research | July 23, 2025, 9:57 AM

Vertex Pharmaceuticals, Inc

Zai Lab Limited ADR

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Zai Lab Limited Unsponsored ADR (ZLAB): Free Stock Analysis Report

Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Mentioned In This Article

Vertex Pharmaceuticals, Inc

Zai Lab Limited ADR

Latest News

6 hours	Vertex Just Reported Trial Results for a Kidney Drug. What It Means for the Stock. VRTX +8.31% Barrons.com
7 hours	Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today VRTX +8.31% StockStory
8 hours	Vertex to seek approval of IgAN drug after Phase III success VRTX +8.31% Clinical Trials Arena
9 hours	This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results VRTX +8.31% Investopedia
9 hours	Oil Crashes 10%, Stocks Rebound On Trump End-Of-War Signals: What's Moving Markets Tuesday? VRTX +8.31% Benzinga
10 hours	What's Going On With CRISPR Therapeutics Stock Today? VRTX +8.31% Benzinga
10 hours	VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study VRTX +8.31% Zacks
13 hours	Vertex's New Kidney Drug Delivers Big Trial Win, Stock Jumps VRTX +8.31% Benzinga
17 hours	These Stocks Are Today's Movers: Occidental, Vertex, HPE, TSMC, Oracle, and More VRTX +8.31% Barrons.com
17 hours	Vertex Stock Jumps. What Wall Street Is Saying About Its Kidney Drug Trial. VRTX +8.31% Barrons.com
Mar-09	Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy VRTX Business Wire
Mar-09	Vertex kidney disease drug hits mark in late-stage study VRTX BioPharma Dive
Mar-08	CRISPR Therapeutics Pivots Beyond Casgevy, Highlights CTX310 Data and New Cardiovascular Push VRTX MarketBeat
Mar-06	Vertex says JOURNAVX demonstrates effective pain management in study VRTX TipRanks
Mar-05	Vertex to Participate in Upcoming March Investor Conferences VRTX Business Wire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)